Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eton Pharmaceuticals CFO Wilson Troutman to retire, James Gruber to succeed » 16:06
04/11/22
04/11
16:06
04/11/22
16:06
ETON

Eton Pharmaceuticals

$3.80 /

-0.44 (-10.38%)

, HZNP

Horizon Therapeutics

$112.06 /

-1.14 (-1.01%)

Eton Pharmaceuticals…

Eton Pharmaceuticals (ETON) announced the appointment of James Gruber as CFO, effective immediately. He succeeds Wilson Troutman, who is retiring. Troutman will remain with the company through the end of May to ensure a transition. Most recently, he was the U.S. Controller at Horizon Therapeutics (HZNP) for seven years, where he oversaw accounting activities for the company during its rapid growth.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$112.06 /

-1.14 (-1.01%)

ETON Eton Pharmaceuticals
$3.80 /

-0.44 (-10.38%)

ETON Eton Pharmaceuticals
$3.80 /

-0.44 (-10.38%)

04/07/22 B. Riley
Eton Pharmaceuticals sales outlook may prove conservative, says B. Riley
03/22/22 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
HZNP Horizon Therapeutics
$112.06 /

-1.14 (-1.01%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$112.06 /

-1.14 (-1.01%)

ETON Eton Pharmaceuticals
$3.80 /

-0.44 (-10.38%)

HZNP Horizon Therapeutics
$112.06 /

-1.14 (-1.01%)

HZNP Horizon Therapeutics
$112.06 /

-1.14 (-1.01%)

Hot Stocks
Eton Pharmaceuticals announces FDA approval of cysteine hydrochloride injection » 07:33
04/11/22
04/11
07:33
04/11/22
07:33
ETON

Eton Pharmaceuticals

$4.24 /

+0.02 (+0.47%)

Eton Pharmaceuticals…

Eton Pharmaceuticals announced that it has received final approval from the U.S. Food and Drug Administration, FDA, for its cysteine hydrochloride abbreviated new drug application, ANDA, a bioequivalent generic of Exela Pharma Sciences' Elcys. Eton was granted 180 days of generic exclusivity as a result of being the first ANDA submitted against the reference product. The 180-day exclusivity period will begin upon Eton's commercialization of the product. Cysteine is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants. Prior to 2019, cysteine was sold in the United States as a "grandfathered" or "unapproved" product. In 2019, Exela Pharma Sciences received FDA approval of its product, which contains the same formulation as the "grandfathered" versions. Eton's partner has manufactured the product in its current formulation as far back as 2003, well before Exela Pharma Sciences began working on its product or filed its patent, and as a result, Eton believes Exela's patents are invalid and should not have been issued by the United States Patent and Trademark Office. Eton is currently engaged with Exela in paragraph IV litigation regarding the validity of Exela's cysteine patents. The trial was held in March 2022 and the company expects a decision from the judge in the third quarter of 2022.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$4.24 /

+0.02 (+0.47%)

ETON Eton Pharmaceuticals
$4.24 /

+0.02 (+0.47%)

04/07/22 B. Riley
Eton Pharmaceuticals sales outlook may prove conservative, says B. Riley
03/22/22 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
ETON Eton Pharmaceuticals
$4.24 /

+0.02 (+0.47%)

Recommendations
Eton Pharmaceuticals sales outlook may prove conservative, says B. Riley » 07:43
04/07/22
04/07
07:43
04/07/22
07:43
ETON

Eton Pharmaceuticals

$4.24 /

-0.05 (-1.17%)

B. Riley analyst Justin…

B. Riley analyst Justin Walsh reiterates a Buy rating on Eton Pharmaceuticals with a $10 price target following the Q4 results. The analyst continues to find the shares attractive at current levels saying the company "poised to breakthrough multiple emerging commercial markets and continue to execute across both internal and partnered product launches." Eton is targeting $25M in fiscal 2022 revenue which may prove to be conservative, including $10M in milestone payments from Azurity and potrntial upside to be derived from continued progress on the recent launch of Rezipres, the Biorphen vial conversion, and pending litigation and subsequent launch of the cysteine hydrochloride injection, Walsh tells investors in a research note.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$4.24 /

-0.05 (-1.17%)

ETON Eton Pharmaceuticals
$4.24 /

-0.05 (-1.17%)

03/22/22 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
ETON Eton Pharmaceuticals
$4.24 /

-0.05 (-1.17%)

  • 08
    Apr
Recommendations
Eton Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright » 06:14
03/22/22
03/22
06:14
03/22/22
06:14
ETON

Eton Pharmaceuticals

$4.27 /

+0.05 (+1.18%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Eton Pharmaceuticals to $11 from $14 and keeps a Buy rating on the shares following the 2021 results. The analyst expects co-promotion of Alkindi Sprinkle with Tolmar to create product momentum in 2022.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$4.27 /

+0.05 (+1.18%)

ETON Eton Pharmaceuticals
$4.27 /

+0.05 (+1.18%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
ETON Eton Pharmaceuticals
$4.27 /

+0.05 (+1.18%)

  • 08
    Apr
Hot Stocks
Eton, XGen announce commercial launch of Rezipres injection » 07:13
03/14/22
03/14
07:13
03/14/22
07:13
ETON

Eton Pharmaceuticals

$3.94 /

+0.125 (+3.28%)

Eton Pharmaceuticals and…

Eton Pharmaceuticals and XGen Pharmaceuticals announced the commercial availability of Rezipres injection. Rezipres is a ready-to-use formulation of injectable ephedrine hydrochloride that is approved for the treatment of clinically important hypotension occurring in the setting of anesthesia. "We are excited to announce yet another new product launch. The availability of Rezipres will provide hospitals with an FDA-approved, ready-to-use ephedrine injection product as an alternative to compounded formats which are not approved by the FDA. We look forward to partnering with XGen DJB given their extensive track record of successfully commercializing injectable products in the hospital setting," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$3.94 /

+0.125 (+3.28%)

ETON Eton Pharmaceuticals
$3.94 /

+0.125 (+3.28%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
ETON Eton Pharmaceuticals
$3.94 /

+0.125 (+3.28%)

  • 08
    Apr
Over a quarter ago
Hot Stocks
Eton, ANI announce commercial availability of Carglumic Acid tablets » 07:35
12/20/21
12/20
07:35
12/20/21
07:35
ETON

Eton Pharmaceuticals

$4.15 /

+0.125 (+3.11%)

, ANIP

ANI Pharmaceuticals

$46.94 /

+0.03 (+0.06%)

Eton Pharmaceuticals…

Eton Pharmaceuticals (ETON) and ANI Pharmaceuticals (ANIP) announced the commercial launch of Carglumic Acid tablets. The product will be marketed by Eton Pharmaceuticals and is the first and only FDA-approved generic version of Carbaglu. It was approved by the FDA for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase, NAGS, deficiency. The product is AB-rated and is bioequivalent and therapeutically equivalent to Carbaglu, which allows pharmacies to substitute it in place of Carbaglu prescriptions. The product application is owned by Novitium Pharmaceuticals, a subsidiary of ANI Pharmaceuticals. "We are excited to offer patients a convenient Carglumic Acid product that does not require refrigeration and to provide it at a lower price than the existing Carbaglu. We believe the adoption of our product will result in significant financial savings to the U.S. healthcare system and to many patients through lower co-pay and co-insurance costs," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. The product application was granted Competitive Generic Therapy designation by the FDA, and as a result, the product is expected to receive 180 days of generic exclusivity.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$4.15 /

+0.125 (+3.11%)

ANIP ANI Pharmaceuticals
$46.94 /

+0.03 (+0.06%)

ETON Eton Pharmaceuticals
$4.15 /

+0.125 (+3.11%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
01/04/21 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $15 from $20 at H.C. Wainwright
ANIP ANI Pharmaceuticals
$46.94 /

+0.03 (+0.06%)

11/02/21 Truist
ANI Pharmaceuticals started at Buy at Truist on revenue growth potential
11/02/21 Truist
ANI Pharmaceuticals initiated with a Buy at Truist
ETON Eton Pharmaceuticals
$4.15 /

+0.125 (+3.11%)

ANIP ANI Pharmaceuticals
$46.94 /

+0.03 (+0.06%)

  • 04
    Nov
  • 08
    Apr
ANIP ANI Pharmaceuticals
$46.94 /

+0.03 (+0.06%)

Earnings
Eton Pharmaceuticals reports Q3 EPS (24c), two estimates (13c) » 16:13
11/15/21
11/15
16:13
11/15/21
16:13
ETON

Eton Pharmaceuticals

$5.10 /

+0.06 (+1.19%)

Reports Q3 revenue…

Reports Q3 revenue $775,000, two estimates $3.04M. Cash and cash equivalents were $22.7 million as of September 30, 2021. "Over the last month we have made tremendous advancements to our commercial portfolio. We gained two more FDA-approved products, EPRONTIA and carglumic acid, both of which should launch in the fourth quarter, and we are increasing ALKINDI SPRINKLE's commercial footprint more than ten-fold through an attractive co-promotion arrangement with Tolmar Pharmaceuticals. These events put us in an even stronger position to deliver significant revenue and reach sustained profitability in 2022," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$5.10 /

+0.06 (+1.19%)

ETON Eton Pharmaceuticals
$5.10 /

+0.06 (+1.19%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
01/04/21 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $15 from $20 at H.C. Wainwright
ETON Eton Pharmaceuticals
$5.10 /

+0.06 (+1.19%)

  • 08
    Apr
Hot Stocks
Eton Pharmaceuticals signs co-promotion agreement for Alkindi Sprinkle » 06:37
11/15/21
11/15
06:37
11/15/21
06:37
ETON

Eton Pharmaceuticals

$5.04 /

+0.16 (+3.28%)

Eton Pharmaceuticals has…

Eton Pharmaceuticals has entered into a multi-year agreement with Tolmar Pharmaceuticals to co-promote Alkindi Sprinkle. Eton will leverage Tolmar's 62-person sales force and their existing relationships in the pediatric endocrinology specialty. Tolmar currently promotes Fensolvi for injectable suspension, indicated for pediatric patients 2 years of age and older with Central Precocious Puberty or CPP. Tolmar's pediatric endocrinology sales force currently promotes the specialty drug Fensolvi for CPP, a rare disease that impacts roughly one in 5,000-10,000 children in the U.S. Tolmar's sales force will promote Alkindi Sprinkler to their pediatric endocrinology targets alongside Fensolvi. Tolmar will receive a royalty on net sales growth above Alkindi Sprinkler's current baseline sales. Eton's sales force will continue to promote the product and Eton will maintain responsibility for all non-sales force related commercial activities. The companies expect Tolmar's sales force to start promoting Alkindi Sprinkler in Decembe

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$5.04 /

+0.16 (+3.28%)

ETON Eton Pharmaceuticals
$5.04 /

+0.16 (+3.28%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
01/04/21 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $15 from $20 at H.C. Wainwright
ETON Eton Pharmaceuticals
$5.04 /

+0.16 (+3.28%)

  • 08
    Apr
Hot Stocks
Eton Pharmaceuticals, Azurity announce FDA approval of EPRONTIA » 06:11
11/08/21
11/08
06:11
11/08/21
06:11
ETON

Eton Pharmaceuticals

$6.25 /

-0.17 (-2.65%)

Eton Pharmaceuticals and…

Eton Pharmaceuticals and Azurity Pharmaceuticals announced that the U.S. FDA has approved EPRONTIA oral solution, 25mg/mL. EPRONTIA is the first oral liquid formulation of topiramate to be approved by the FDA. Azurity will be responsible for commercializing the product and anticipates product availability before year end. Eton will receive a $5M milestone payment upon EPRONTIA's commercial launch, a royalty on net sales, and potential commercial milestones.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$6.25 /

-0.17 (-2.65%)

ETON Eton Pharmaceuticals
$6.25 /

-0.17 (-2.65%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
01/04/21 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $15 from $20 at H.C. Wainwright
ETON Eton Pharmaceuticals
$6.25 /

-0.17 (-2.65%)

  • 08
    Apr
Hot Stocks
Eton Pharmaceuticals acquires marketing rights to carglumic acid tablets » 07:41
10/28/21
10/28
07:41
10/28/21
07:41
ETON

Eton Pharmaceuticals

$5.64 /

-0.02 (-0.35%)

Eton Pharmaceuticals…

Eton Pharmaceuticals announced that it has acquired U.S. marketing rights to carglumic acid tablets. The product's Abbreviated New Drug Application, which is owned by Novitium Pharma, was approved by the U.S. Food and Drug Administration on October 13, 2021. The product is an AB-rated, substitutable generic version of Carbaglu. "We are pleased to be offering patients a lower cost alternative to one of the most expensive treatments in the world," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "With our existing orphan drug commercial footprint and robust patient support services, we believe we are well positioned to commercialize this product. We look forward to working with Novitium to bring the product to patients later this year," Brynjelsen added.

ShowHide Related Items >><<
ETON Eton Pharmaceuticals
$5.64 /

-0.02 (-0.35%)

ETON Eton Pharmaceuticals
$5.64 /

-0.02 (-0.35%)

10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
10/14/21 B. Riley
Eton Pharmaceuticals resumed with a Buy at B. Riley
06/01/21 B. Riley
Eton Pharmaceuticals price target lowered to $11 from $13 at B. Riley
01/04/21 H.C. Wainwright
Eton Pharmaceuticals price target lowered to $15 from $20 at H.C. Wainwright
ETON Eton Pharmaceuticals
$5.64 /

-0.02 (-0.35%)

  • 08
    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.